Clinical Trial

A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

Name: A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis — clinical trial record (NCT07719023)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a phase 3 clinical study conducted in China. The primary objective is to compare the efficacy and safety of AK3280 400 mg versus placebo and active control (pirfenidone) in IPF patients.

Trial Details

NCT Number	NCT07719023
Lead Sponsor	Shanghai Ark Biopharmaceutical Co., Ltd.
Conditions	Idiopathic Pulmonary Fibrosis (IPF)
Enrollment	263 participants
Start Date	2026-08-31
Primary Completion	2028-09-30 (estimated)
Study Completion	2029-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-22